Peptide Initiative

Peptides · Peptide comparison

Defensin (HBD-3) vs Thymalin

Most potent human beta-defensin (45 amino acids) with unique salt-insensitive antimicrobial activity — kills MRSA at MIC 0.5-1.0 μg/mL regardless of salt concentration, disrupts biofilms at 4-8 μg/mL, and retains full bactericidal function even without its disulfide bonds — representing a next-generation antimicrobial peptide template for combating antibiotic resistance

Russian thymic peptide complex that rejuvenates immune function and supports healthy aging

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeDefensin (HBD-3)200–200 mcg/mLThymalin5–10 mg
FrequencyDefensin (HBD-3)As neededThymalinOnce daily
AdministrationDefensin (HBD-3)Topical application (research/wound care)ThymalinIntramuscular injection
Cycle lengthDefensin (HBD-3)Ongoing/indefiniteThymalin4-6 weeks
Onset speedDefensin (HBD-3)Rapid (hours to days)ThymalinModerate (1-2 weeks)
Evidence levelDefensin (HBD-3)Moderate human trials (Phase 1-2)ThymalinLimited human trials

Efficacy

Benefit ratings

Fighting Drug-Resistant Bacteria

Defensin (HBD-3)96%
ThymalinNo recorded rating

Wound Healing

Defensin (HBD-3)88%
ThymalinNo recorded rating

Immune System Support

Defensin (HBD-3)82%
ThymalinNo recorded rating

Immune Restoration

Defensin (HBD-3)No recorded rating
Thymalin88%

Longevity Support

Defensin (HBD-3)No recorded rating
Thymalin82%

Disease Prevention

Defensin (HBD-3)No recorded rating
Thymalin78%

Technical data

Compound specifications

Defensin (HBD-3)

Molecular formula
Approximately C220H340N64O62S6 (45-amino acid peptide with 3 disulfide bonds)
Molecular weight
~5,155 Da (mature peptide)
Half-life
Short systemic half-life (minutes) typical of cationic peptides; disulfide-bonded form provides protease resistance at local tissue sites; linear form shows adequate stability for topical applications
Bioavailability
Topical application achieves high local concentrations; maintains activity in physiological salt environments (unique); linear form retains activity enabling simplified formulation; not intended for oral or systemic delivery
CAS number
Not assigned (endogenous human peptide; research-grade available from peptide suppliers)

Thymalin

Molecular formula
Complex mixture; active dipeptide EW: C16H19N3O5
Molecular weight
Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da
Half-life
Not precisely characterized for complex; immune effects persist weeks post-administration
Bioavailability
High via intramuscular or subcutaneous injection
CAS number
63958-90-7

Protocols

Dosing compared

Defensin (HBD-3)

Topical

  • 200 µg/mL applied to the wound, about 4 µg per dose (20 µL)Every 2 days in the study · Until wound healed (study setting)HBD-3 is a research-only peptide with no human dosing protocol. No published study gives a topical peptide dose: the infected-diabetic-wound study on this page delivered hBD-3 by gene transfer, not as an applied peptide [6], so this amount is unsourced. Human use has not been established.

Thymalin

Intramuscular injection

  • 5-10 mg reconstituted in salineOnce daily · 5-10 day course, often repeated every 6 monthsReflects the Russian clinical course used in immune-restoration and gerontology protocols, typically 10 mg IM daily for 5-10 days [1].

Subcutaneous injection

  • 10 mgOnce daily · Up to 20 day course, repeated every 6 monthsSubcutaneous administration is used in community practice at the same 10 mg daily dosing; longer 20-day courses are described for cyclical immune support [1].

Applications

Best suited for

Defensin (HBD-3)

Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of antimicrobial wound dressings and medical device coatings
Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-biofilm strategies for chronic wound infections and implant-associated infections
Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Applications requiring antimicrobial activity in physiological or high-salt environments
Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymalin

Aging Adults Seeking Immune Support
Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.
Longevity and Anti-Aging Protocols
Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.
Seasonal Illness Prevention
Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety profile

Side effects

Defensin (HBD-3)

Common

  • Local site irritation
  • Transient inflammatory response
  • Mild wound bed changes

Uncommon

  • Localized allergic reaction
  • Mild cytotoxicity at high concentrations

Serious

  • No serious adverse effects documented at therapeutic concentrations

Thymalin

Common

  • No side effects in most patients
  • Mild injection site reaction

Uncommon

  • Transient low-grade fever
  • Mild flu-like symptoms
  • Temporary headache

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Defensin (HBD-3)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Defensin HBD-3 is not FDA-approved and has no completed human clinical trials, existing only in research contexts with in vitro and animal study data. Animal toxicology studies demonstrate no major systemic toxicity at doses exceeding therapeutic levels, but human immunological responses to exogenously administered defensin peptides have not been characterized. Risks include potential immune activation, cross-reactivity with self-antigens (due to HBD-3 expression in healthy epithelial cells), development of anti-peptide antibodies, and possible tolerance development with repeated dosing. Bacterial and fungal resistance to defensin-based therapy is theoretically possible. No human pharmacokinetics, dose-ranging studies, Phase 1 safety assessments, or clinical efficacy data exist.

Contraindications

  • Known hypersensitivity to defensin peptides or formulation components
  • Pregnancy and breastfeeding — insufficient safety data for exogenous defensin administration
  • Active autoimmune conditions — potential for immune activation through monocyte/macrophage recruitment
  • Severe hepatic or renal impairment — peptide clearance may be altered for any systemic exposure

Thymalin

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

Contraindications

  • Active thymic tumors or malignancies
  • Known hypersensitivity to animal-derived peptide products
  • Pregnancy and breastfeeding (insufficient safety data)
  • Severe uncontrolled autoimmune disease without medical supervision

Decision guide

Which is right for you?

Defensin (HBD-3)

Choose Defensin (HBD-3) if…

  • Research into anti-MRSA therapeutics and alternatives to vancomycin for resistant infections
  • Development of antimicrobial wound dressings and medical device coatings
  • Anti-biofilm strategies for chronic wound infections and implant-associated infections
  • Applications requiring antimicrobial activity in physiological or high-salt environments

Thymalin

Choose Thymalin if…

  • Immune system restoration in aging adults
  • Longevity and healthy aging support
  • Reducing infection frequency and severity
  • Multi-system health optimization